Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian D Davis

Showing results (161-170 of 282) with videos related to

Pageof 29
Sort By:
Oncoimmunology|June 5, 2013
Human perforin mutations and susceptibility to multiple primary cancersJoseph A Trapani, Kevin Y T Thia, Miles Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinomaThomas E Hutson, Ian D Davis, Jean-Pascal H Machiels, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|July 14, 2016
In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PETPeter K Wong, Sze Ting Lee, Carmel Murone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
The Medical Journal of Australia|June 4, 2013
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011Sue M Evans, Jeremy L Millar, Ian D Davis, et al.
BMC Cancer|August 31, 2018
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumoursNicola J Lawrence, Howard Chan, Guy Toner, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Cancer Immunity|February 23, 2005
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanomaAndrew M Scott, Zhanqi Liu, Carmel Murone, et al.
Pageof 29

Showing results (161-170 of 282) with videos related to

Sort By:
Pageof 29
Oncoimmunology|June 5, 2013
Human perforin mutations and susceptibility to multiple primary cancersJoseph A Trapani, Kevin Y T Thia, Miles Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinomaThomas E Hutson, Ian D Davis, Jean-Pascal H Machiels, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|July 14, 2016
In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PETPeter K Wong, Sze Ting Lee, Carmel Murone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
The Medical Journal of Australia|June 4, 2013
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011Sue M Evans, Jeremy L Millar, Ian D Davis, et al.
BMC Cancer|August 31, 2018
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumoursNicola J Lawrence, Howard Chan, Guy Toner, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup> Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Cancer Immunity|February 23, 2005
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanomaAndrew M Scott, Zhanqi Liu, Carmel Murone, et al.
Pageof 29